Liposome encapsulated polydopamine nanoparticles: Enhancing ferroptosis and activating hypoxia prodrug activity

Guo, Yijun; Luo, Huiling; Jiang, Hairong; Liu, Xinxin; Long, Xinrui; Hou, Yinuo; Chen, Zhou; Sun, Yanan; Ge, Dongtao; Shi, Wei

doi:10.1016/j.mtbio.2024.101009

Cited by 1 publication

(1 citation statement)

References 54 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PTT, known for its capacity to inflict damage on vascular endothelial cells, presents a mechanism of action complementary to that of VDAs. The thermal damage induced by PTT can cause immediate destruction of the existing tumor vasculature, creating a hypoxic environment and enhancing the tumor’s susceptibility to further treatment. , When VDAs are used in conjunction with PTT, they can capitalize on the compromised vasculature and exert their effects more profoundly, potentially leading to complete tumor devascularization and subsequent tumor cell death. The synergy between VDAs and PTT, therefore, promises a more effective cancer treatment strategy.…”

Section: Introductionmentioning

confidence: 99%

Peptide-IR820 Conjugate: A Promising Strategy for Efficient Vascular Disruption and Hypoxia Induction in Melanoma

Zhang,

Jiang,

Xing

et al. 2024

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Photothermal therapy (PTT) has emerged as a noninvasive and precise cancer treatment modality known for its high selectivity and lack of drug resistance. However, the clinical translation of many PTT agents is hindered by the limited biodegradability of inorganic nanoparticles and the instability of organic dyes. In this study, a peptide conjugate, IR820-Cys-Trp-Glu-Trp-Thr-Trp-Tyr (IR820-C), was designed to self-assemble into nanoparticles for both potent PTT and vascular disruption in melanoma treatment. When co-assembled with the poorly soluble vascular disrupting agent (VDA) combretastatin A4 (CA4), the resulting nanoparticles (IR820-C@CA4 NPs) accumulate efficiently in tumors, activate systemic antitumor immune responses, and effectively ablate melanoma with a single treatment and nearinfrared irradiation, as confirmed by our in vivo experiments. Furthermore, by exploiting the resulting tumor hypoxia, we subsequently administered the hypoxia-activated prodrug tirapazamine (TPZ) to capitalize on the created microenvironment, thereby boosting therapeutic efficacy and antimetastatic potential. This study showcases the potential of short-peptide-based nanocarriers for the design and development of stable and efficient photothermal platforms. The multifaceted therapeutic strategy, which merges photothermal ablation with vascular disruption and hypoxia-activated chemotherapy, holds great promise for advancing the efficacy and scope of cancer treatment modalities.

show abstract

Section: Introductionmentioning

confidence: 99%